Format
Sort by
Items per page

Send to

Choose Destination

Best matches for oncolytic reovirus:

Search results

Items: 1 to 20 of 271

1.

Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: focus on fiber chimerism and mosaicism, hexon and pIX.

Stepanenko AA, Chekhonin VP.

Virus Res. 2018 Aug 17. pii: S0168-1702(18)30413-1. doi: 10.1016/j.virusres.2018.08.012. [Epub ahead of print] Review.

PMID:
30125593
2.

Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection.

Bourhill T, Mori Y, Rancourt DE, Shmulevitz M, Johnston RN.

Viruses. 2018 Aug 11;10(8). pii: E421. doi: 10.3390/v10080421. Review.

3.

Characterization of a replicating expanded tropism oncolytic reovirus carrying the adenovirus E4orf4 gene.

Kemp V, Dautzenberg IJC, Cramer SJ, Hoeben RC, van den Wollenberg DJM.

Gene Ther. 2018 Jul 16. doi: 10.1038/s41434-018-0032-9. [Epub ahead of print]

PMID:
30013187
4.

25-hydroxycholesterol Production by Interferon Stimulated Gene Cholesterol-25-hydroxylase Restricts Mammalian Reovirus Infection.

Doms A, Sanabria T, Hansen JN, Altan-Bonnet N, Holm GH.

J Virol. 2018 Jun 27. pii: JVI.01047-18. doi: 10.1128/JVI.01047-18. [Epub ahead of print]

PMID:
29950420
5.

Current understanding of reovirus oncolysis mechanisms.

Phillips MB, Stuart JD, Rodríguez Stewart RM, Berry JT, Mainou BA, Boehme KW.

Oncolytic Virother. 2018 Jun 14;7:53-63. doi: 10.2147/OV.S143808. eCollection 2018. Review.

6.

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.

Mostafa AA, Meyers DE, Thirukkumaran CM, Liu PJ, Gratton K, Spurrell J, Shi Q, Thakur S, Morris DG.

Cancers (Basel). 2018 Jun 15;10(6). pii: E205. doi: 10.3390/cancers10060205.

7.

Oncolytic Viruses for Multiple Myeloma Therapy.

Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST.

Cancers (Basel). 2018 Jun 14;10(6). pii: E198. doi: 10.3390/cancers10060198. Review.

8.

A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma.

Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM.

Cancers (Basel). 2018 May 25;10(6). pii: E160. doi: 10.3390/cancers10060160.

9.

The emerging role of oncolytic virus therapy against cancer.

Russell L, Peng KW.

Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04.

10.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
11.

Synergistic antitumour effects of rapamycin and oncolytic reovirus.

Comins C, Simpson GR, Rogers W, Relph K, Harrington K, Melcher A, Roulstone V, Kyula J, Pandha H.

Cancer Gene Ther. 2018 May 3. doi: 10.1038/s41417-018-0011-8. [Epub ahead of print]

PMID:
29720674
12.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Mar 8. pii: S1533-0028(17)30462-0. doi: 10.1016/j.clcc.2018.03.001. [Epub ahead of print]

PMID:
29653857
13.

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.

Tremblay-LeMay R, Rastgoo N, Chang H.

J Hematol Oncol. 2018 Mar 27;11(1):46. doi: 10.1186/s13045-018-0589-1. Review.

14.

Oncolytic Reovirus Inhibits Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in a TLR3-Dependent Manner.

Katayama Y, Tachibana M, Kurisu N, Oya Y, Terasawa Y, Goda H, Kobiyama K, Ishii KJ, Akira S, Mizuguchi H, Sakurai F.

J Immunol. 2018 Apr 15;200(8):2987-2999. doi: 10.4049/jimmunol.1700435. Epub 2018 Mar 19.

PMID:
29555782
15.

Anti-tumor efficacy of oncolytic reovirus against gastrointestinal stromal tumor cells.

Inagaki Y, Kubota E, Mori Y, Aoyama M, Kataoka H, Johnston RN, Joh T.

Oncotarget. 2017 Dec 18;8(70):115632-115646. doi: 10.18632/oncotarget.23361. eCollection 2017 Dec 29.

16.

Correction: Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus.

Zhao X, Ouyang W, Chester C, Long S, Wang N, He Z.

PLoS One. 2018 Jan 25;13(1):e0192090. doi: 10.1371/journal.pone.0192090. eCollection 2018.

17.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

18.

Baculovirus-assisted Reovirus Infection in Monolayer and Spheroid Cultures of Glioma cells.

Dautzenberg IJC, van den Hengel SK, de Vrij J, Ravesloot L, Cramer SJ, Hong SS, van den Wollenberg DJM, Boulanger P, Hoeben RC.

Sci Rep. 2017 Dec 15;7(1):17654. doi: 10.1038/s41598-017-17709-z.

19.

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.

Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST.

Oncotarget. 2017 Sep 30;8(49):86769-86783. doi: 10.18632/oncotarget.21423. eCollection 2017 Oct 17.

20.

Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.

Hwang CC, Igase M, Sakurai M, Haraguchi T, Tani K, Itamoto K, Shimokawa T, Nakaichi M, Nemoto Y, Noguchi S, Coffey M, Okuda M, Mizuno T.

Vet Comp Oncol. 2018 Jun;16(2):229-238. doi: 10.1111/vco.12361. Epub 2017 Oct 27.

PMID:
29076241

Supplemental Content

Loading ...
Support Center